FDA Approves Breakthrough KRAS Inhibitor Lumakras for Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sotorasib (Lumakras) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. The approval, announced on May 28, 2021, marks a historic milestone as the first targeted therapy for KRAS G12C mutations, which occur in approximately 13% of NSCLC cases.

The breakthrough designation addresses a significant unmet need in NSCLC treatment, where KRAS mutations have long been considered "undruggable." Sotorasib works by specifically inhibiting KRAS G12C, a protein that drives cancer growth.

Pivotal Trial Results

The FDA's decision was based on results from the CodeBreaK 100 trial (NCT03600883), which demonstrated compelling efficacy in previously treated NSCLC patients. The study showed:

• Objective response rate (ORR) of 36% (95% CI: 28-45)
• Median duration of response of 10 months
• Disease control rate of 81%
• Median progression-free survival of 6.8 months

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for oncology, with sotorasib most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Safety Profile

The safety analysis included 359 patients who received sotorasib 960 mg daily. The most common adverse reactions (≥ 20%) included:

• Diarrhea (42%)
• Musculoskeletal pain (35%)
• Nausea (25%)
• Fatigue (21%)

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Clinical Impact and Implementation

Dr. Roy Herbst, Chief of Medical Oncology at Yale Cancer Center, commented: "The approval of sotorasib represents a significant advancement in precision medicine for lung cancer. This targeted therapy offers new hope for patients with KRAS G12C mutations who previously had limited treatment options."

The drug manufacturer has announced that sotorasib will be available through specialty pharmacies within one week of approval. The recommended dose is 960 mg (eight 120 mg tablets) taken orally once daily.

Frequently Asked Questions

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for oncology pricing, access, and launch sequencing.

Future Development

Ongoing clinical trials are investigating sotorasib in various combinations and earlier treatment settings. The confirmatory Phase 3 CodeBreaK 200 trial (NCT04303780) comparing sotorasib to docetaxel in KRAS G12C-mutated NSCLC is currently enrolling patients.

The manufacturer is required to submit additional clinical data to the FDA as part of the accelerated approval process to confirm the drug's clinical benefit.

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-30.

IntelligenceStrategic Takeaways▾

The FDA has approved Lumakras, a groundbreaking KRAS inhibitor, providing a new targeted therapy option for patients battling lung cancer.

Related profiles

• sotorasib

Related coverage

• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer
• EMA backs datopotamab deruxtecan, but lung cancer access remains unclear